<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001996</url>
  </required_header>
  <id_info>
    <org_study_id>053B</org_study_id>
    <secondary_id>05</secondary_id>
    <nct_id>NCT00001996</nct_id>
  </id_info>
  <brief_title>A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole</brief_title>
  <official_title>A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the safety of atovaquone (566C80) with intravenous (IV) pentamidine for the&#xD;
      treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients who are&#xD;
      intolerant of therapy with trimethoprim / sulfamethoxazole (TMP / SMX) by comparing the&#xD;
      incidence of premature discontinuation of therapy due to toxicity. To compare the efficacy of&#xD;
      566C80 with intravenous (IV) pentamidine for the treatment of mild to moderate PCP in the&#xD;
      same population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  History of, or are currently experiencing, intolerance to TMP / SMX, or to another&#xD;
             sulfonamide, which required discontinuation of therapy.&#xD;
&#xD;
          -  Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Willing and able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded.&#xD;
&#xD;
          -  Malabsorption disorder or vomiting that would, in the judgement of the investigator,&#xD;
             potentially limit the retention and absorption of an oral therapy.&#xD;
&#xD;
          -  Concurrent bacterial, fungal, or viral pneumonitis, pulmonary Kaposi's sarcoma, or&#xD;
             other concurrent illness, or chronic pulmonary disease that, in the investigator's&#xD;
             opinion, would make interpretation of drug efficacy difficult.&#xD;
&#xD;
          -  Present occurrences of abnormal prolongation of QT interval on standard, 12 lead EKG.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Drugs with potential anti-pneumocystis effect (eg:&#xD;
&#xD;
          -  sulfonamides, dapsone, trimethoprim, other dihydrofolate reductase (DHFR) inhibitors,&#xD;
             primaquine, clindamycin, sulfonylureas).&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Zidovudine.&#xD;
&#xD;
          -  Investigational agents including anti-retroviral agents (ddI, ddC, etc.). Patients&#xD;
             receiving these drugs prior to entry must discontinue their use during the therapy&#xD;
             phase (21 days) of the trial.&#xD;
&#xD;
          -  Corticosteroids (except replacement therapy) during the 21 day treatment period&#xD;
             (Strata A and C Patients).&#xD;
&#xD;
          -  Class 1A antiarrhythmics (ie:&#xD;
&#xD;
          -  quinidine, procainamide, disopyramide).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Judged by the investigator to be in impending respiratory failure.&#xD;
&#xD;
          -  Known intolerance to parenteral pentamidine isethionate, or therapeutic failure with&#xD;
             same for treatment of current episode of PCP.&#xD;
&#xD;
          -  Significant psychosis or emotional disorder that, in the investigator's opinion, would&#xD;
             preclude the patient from adhering to the protocol.&#xD;
&#xD;
          -  Inability or unwillingness to take medication orally or with food.&#xD;
&#xD;
          -  Prior documented glucose-6-phosphate dehydrogenase (G6PD) deficiency.&#xD;
&#xD;
          -  History, or present occurrences, of abnormal prolongation of QT interval on standard,&#xD;
             12 lead EKG.&#xD;
&#xD;
          -  Termination from FDA 053A due to toxicity.&#xD;
&#xD;
          -  For patients entering under historic intolerance criteria (Groups A and B), prior&#xD;
             therapy for this episode of PCP is an exclusion.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment within 4 weeks of entry for a prior episode of PCP.&#xD;
&#xD;
          -  For patients entering under historic intolerance criteria (Groups A and B), prior&#xD;
             therapy for this episode of PCP is an exclusion.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Adjuvant prednisone for patient enrolled in Strata B or D.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Bay AIDS Ctr</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Hosp</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <zip>90710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Med Ctr</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Research Consortium</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davies Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Patrick Joseph</name>
      <address>
        <city>San Ramone</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Research Consortium of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Gen Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston City Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp and Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Med Ctr at Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gathe, Joseph, M.D.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dohn M, Weinberg W, Rosenstock J, Follansbee S, Torres R, Caldwell P. Atovaquone vs. pentamidine for pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1993 Jun 6-11;9(1):372 (abstract no PO-B10-1421)</citation>
  </reference>
  <verification_date>May 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>atovaquone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

